SPLEEN STIFFNESS MEASUREMENT BY A DEDICATED 100Hz VIBRATION-CONTROLLED TRANSIENT ELASTOGRAPHY PROBE IMPROVES THE NON-INVASIVE DIAGNOSIS OF CLINICALLY SIGNIFICANT PORTAL HYPERTENSION IN A PROSPECTIVE MULTICENTER STUDY

<div><p><b>Background:</p> </b><p>Non-invasive diagnostic tools for clinically significant portal hypertension (CSPH) have been developed in the ANTICIPATE study/subsequent work (liver stiffness measurement (LSM) and platelet count (PLT) ± BMI) and endorsed by the Baveno VII consensus. A dedicated 100Hz probe for spleen stiffness measurement (SSM) substantially increased its clinical applicability, but limited data exists on the diagnostic performance of SSM (100Hz) for CSPH as well as its ability to improve the ANTICIPATE±NASH models.</p>

IMMEDIATE POSTPARTUM CESSATION OF TENOFOVIR IN HIGHLY VIREMIC PREGNANT MOTHERS WITH CHRONIC HEPATITIS B INFECTION: MATERNAL AND INFANT OUTCOMES

<div><p><strong><b>Background:</strong> </b></p>
<div><p><span lang="EN-US">Antiviral prophylaxis with tenofovir disoproxil fumarate (TDF) during pregnancy is the current standard of care to prevent mother-to-child transmission (MTCT) of chronic hepatitis B (CHB) infection in highly viremic mothers. We investigated the maternal and fetal outcomes in a large Chinese cohort of TDF-treated CHB pregnant subjects.</span></p></div>
<div><p></p></div>

ONGOING EXPERIENCE OF IMPLEMENTING "THE TORONTO PROTOCOL": AN ULTRA-SHORT COURSE GLECAPRIVER/PIBRENTASVIR WITH EZETIMIBE FOR SOLID ORGAN TRANSPLANTATION FROM HCV-INFECTED DONORS TO HCV-UNINFECTED RECIPIENTS

<div><p><strong>Background</strong>: The ongoing overdose crisis has led to an increase in transplantation of organs from HCV-infected donors (D+) to uninfected recipients (R-). We previously showed that an ultra-short course (1 day pre and 7 days post) of glecaprevir/pibrentasvir (G/P) combined with ezetimibe (E) prevented chronic infection in non-liver solid organ recipients.

NON SELECTIVE BETA BLOCKER REDUCES MORTALITY OF CIRRHOSIS PATIENTS ADMITTED TO INTENSIVE CARE UNIT WITH ACUTE DECOMPENSATION

<div><p><b>Background: </b>Non-selective-beta-blockers (NSBB) are main stay of therapy in portal hypertension management. Apart from direct portal pressure reduction, NSBB’s modulate inflammatory cascade, which could be beneficial in patients with acute decompensation (AD). We therefore aimed to evaluate effect of NSBB on 28-day mortality and markers of systemic inflammation in a propensity score matched (PSM) cohort of AD patients requiring intensive care unit(ICU) admission.</p>

Itfg1: A PROMISING TARGET FOR ENHANCED LIVER REGENERATION AND CHRONIC LIVER DISEASE TREATMENT

<div><p><b>Background: </b>The liver has a remarkable regenerative capacity. Nevertheless, under chronic liver-damaging conditions, this capacity becomes exhausted, allowing the accumulation of fibrotic tissue and leading to end-stage liver disease. Enhancing the endogenous regenerative capacity by targeting regeneration breaks is a novel therapeutic approach. We set up an in vivo functional genetic screen to identify such regeneration breaks. Integrin Alpha FG-GAP Repeat Containing 1 (ITFG1) was one of the top hits.

EFFECTS OF MICROPLASTICS ON THE HEPATIC TRANSCRIPTOME

<div><p><b>Background:<span> </b>Pollution from plastics is an increasing health threat. Microplastics are small plastic pieces, which are formed by direct synthesis for industrial or consumer applications as well as by environmental plastic degradation. As plastic degradation is increased by UV light and “weathering”, global warming has increased environmental microplastics.

THE SIGNIFICANT ASSOCIATION BETWEEN PNPLA3 G ALLELE AND ADVANCED FIBROSIS IN CHILDREN WITH NAFLD IS FURTHER INFLUENCED BY BMI AND type2 DIABETES

<div><p><b>Background:</p> </b><p><em>PNPLA3</em> rs738409 polymorphism, obesity, and type 2 diabetes mellitus (T2DM) are strongly associated with non-alcoholic fatty liver disease (NAFLD) and its severity in children. Whether <em>PNPLA3</em> rs738409-related predisposition to NAFLD severity is influenced by obesity and T2DM in children with NAFLD is not known.

RGS rs35197737 IN CHROMOSOME 1 IS ASSOCIATED WITH RISK OF STATIN INDUCED LIVER INJURY: RESULTS FROM THE DRUG INDUCED LIVER INJURY NETWORK (DILIN)

<div><p><b>Background: </b>Statins may very rarely cause drug induced liver injury (DILI) but its pathogenesis is not well understood. Genetic factors may play a role in the pathogenesis of liver injury due to selected agents. In this study, we investigated genetic factors associated with statin DILI through a genome wide association study (GWAS).</p>

A PILOT STUDY OF MULTIPLEXED PROTEOMIC NEWBORN SCREENING FOR WILSON DISEASE IN WA STATE

<div><p><b>Background:</p> </b><p>Newborn Screening (NBS) is successful in identifying infants with fatal but treatable disorders enabling early intervention with favorable outcomes. Unfortunately, many congenital disorders in particular Wilson disease do not feature specific metabolic biomarkers nor analytical methods suitable for NBS even where highly effective preemptive treatments are available.

AN AGE-STATIN INTERPLAY IN PREVENTING THE DEVELOPMENT OF CIRRHOSIS IN A 10-YEAR COHORT OF PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)

<div><p><b>Background:</p> </b><p>Statins reduce the risk of hepatic fibrosis in patients with chronic liver diseases. Since age, sex, and menopausal status modulate NAFLD pathogenesis and fibrosis risk, the effects of statins on hepatic fibrosis may vary by age and sex. We aimed to assess age-/sex-disparities in the association between statin use and the incidence of cirrhosis in patients with NAFLD.</p>

Subscribe to